The effect of taking antibiotic on treatment of Helicobacter pylori infection

Comparison of standard triple therapy with sequential therapy With base of levofloxacin and tinidazole in eradication of Helicobacter Pylori in patients with duodenal ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110124823N1

Enrollment

168

Registered

2015-12-24

Start date

2015-10-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Duodenal ulcer. Condition 2: Helicobacter Pylori. erosion (acute) of duodenum, ulcer (peptic): duodenal-postpyloric Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Group I (Intervention group): Patients, the first five days, receives pantoprazole, 40 mg twice daily, plus amoxicillin, 1 gm twice daily and the next five days receives pantoprazole,

Treatment - Drugs

Group I (Intervention group): Patients, the first five days, receives pantoprazole, 40 mg twice daily, plus amoxicillin, 1 gm twice daily and the next five days receives pantoprazole, 40mg twice daily

Group II (Control group): Pateints receives omeprazole, 20 mg plus amoxicillin 1gr and clarithromycin 500 mg (All three drugs twice daily) for 10 days

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with symptoms of dyspepsia, epigastric pain, nausea, vomiting, melena, hematemesis; Patients with duodenal ulcer; Patients with ages: 20-70. Exclusion Criteria: History of treatment of Helicobacter pylori; taking antibiotics; history of previous surgery on the stomach like total gastrectomy and gastrojejunostomy; history of drug allergies; liver cirrhosis; uremia; pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori infection. Timepoint: Before treatment and 8 week after completion of treatment. Method of measurement: Urea breath test with C14.;Helicobacter pylori infection. Timepoint: Before treatment and 8 week after completion of treatment. Method of measurement: Endoscopy.	—

Secondary

Measure	Time frame
Nausea and vomiting. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Abdominal pain. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Watery diarrhea. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Secretion or vaginal itching. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.	—

Measure

Time frame

Nausea and vomiting. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Abdominal pain. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Watery diarrhea. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.;Secretion or vaginal itching. Timepoint: Every three days during treatment period. Method of measurement: Verbal questionnaire and the patient's response.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Hamedifar

Ahvaz Jundishapur University of Medical Sciences

drshahramhamedifar@gmail.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026